A Phase 3 interventional study of Rivaroxaban (Xarelto, BAY59-7939) and Rivaroxaban-Placebo in Peripheral Artery Disease, sponsored by Bayer. Completed at 533 sites in 34 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2020-12-08.
Sponsored by Bayer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing rivaroxaban in Peripheral Arterial Disease — 3 open to participants now, 3 under way, none of them phase 3. Rivaroxaban · Peripheral Arterial Disease.
Among the 13 studies testing rivaroxaban in Peripheral Arterial Disease, this one is the 2nd largest by enrollment, is the only one that started in 2015, is one of 2 in phase 3, and was the 2nd registered.
1,377 studies on the registry are indexed under Peripheral Arterial Disease; 275 are open to participants now.
Browse Peripheral Arterial Disease studies →3 of the 13 studies testing rivaroxaban in Peripheral Arterial Disease are open now, in 3 countries. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
Science Valley Research Institute · Sites in Brazil
Seoul National University Bundang Hospital · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 192 Peripheral Arterial Disease studies recruiting now, 138 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6,564 is above the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.
Median enrollment 100 across the 13 interventional studies. Of the 7 that completed or were terminated, 3 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 13 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
10 studies in Peripheral Arterial Disease by Bayer: none open now, none under way, none of them phase 3. Of 10 finished, 2 (20%) have results posted.
Among the 10 studies in Peripheral Arterial Disease by Bayer, this one is the only one that started in 2015, is one of 3 in phase 3, and was the 6th registered.
Bayer’s Peripheral Arterial Disease studies by the year they started, since 2004.
2 of the studies testing rivaroxaban in Peripheral Arterial Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07613840Massachusetts General HospitalPersonalizing Thromboprophylaxis for Patients With Peripheral Artery Disease | 2027-04-29 |
| NCT07796217Seoul National University Bundang HospitalComparison of Clopidogrel-based Antiplatelet Agent Treatment and Aspirin Plus Low Dose Rivaroxaban Therapy | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies testing rivaroxaban in Peripheral Arterial Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 10 in Peripheral Arterial Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of study was to test whether rivaroxaban added to standard of care treatment, when compared to placebo, had the potential to reduce the incidence of the clinical events related to the clots and complications of the heart and brain (CV death, MI, or stroke) or the legs (acute limb ischemia or major amputation) in patients who had undergone recent procedure(s) to improve the blood flow of their legs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Rivaroxaban 2.5 mg orally twice daily (5 mg cumulative daily dose)
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Rivaroxaban-placebo orally twice daily
Drug: Rivaroxaban-Placebo
2.5 mg, twice daily, orally, tablet
matching placebo, twice daily, orally, tablet
Primary Efficacy Outcome: Number of Participants With Composite of Myocardial Infarction (MI), Ischemic Stroke, Cardiovascular Death, Acute Limb Ischemia (ALI) and Major Amputation Due to a Vascular Etiology
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.
Time frame: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean time in follow-up survival time until ECOD that date was 1109.76 days.
Primary Safety Outcome: Number of Participants With TIMI (Thrombolysis in Myocardial Infarction) Major Bleeding
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.
Time frame: For each participant, the first occurrence of the primary safety outcome after randomization up until 2 days after permanent stop of study drug (rivaroxaban or rivaroxaban placebo).
Number of Participants With Composite of MI, Ischemic Stroke, Coronary Heart Disease (CHD) Death, ALI, and Major Amputation of a Vascular Etiology
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.
Time frame: For each participant, the first occurrence of the composite efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1108.79 days.
Number of Participants With an Unplanned Index Limb Revascularization for Recurrent Limb Ischemia (Subsequent Index Leg Revascularization That Was Not Planned or Considered as Part of the Initial Treatment Plan at the Time of Randomization)
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.
Time frame: For each participant, the first occurrence of the efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1062.48 days.
Number of Participants With Hospitalization for a Coronary or Peripheral Cause (Either Lower Limb) of a Thrombotic Nature
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.
Time frame: For each participant, the first occurrence of the efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1154.04 days
Number of Participants With Composite of MI, Ischemic Stroke, All-cause Mortality (ACM), ALI, and Major Amputation of a Vascular Etiology
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.
Time frame: For each participant, the first occurrence of the composite efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1085.13 days
Number of Participants With Composite of MI, All-cause Stroke, Cardiovascular (CV) Death, Acute Limb Ischemia (ALI), and Major Amputation of a Vascular Etiology
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.
Time frame: For each participant, the first occurrence of the composite efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1108.29 days
Number of Mortality (All-cause)
Time frame: For each participant, the first occurrence of the outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1188.48 days
Number of Participants With Venous Thromboembolic (VTE) Events
Venous thromboembolic events were reported by investigator only.
Time frame: For each participant, the first occurrence of the outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1187.65 days
Secondary Safety Outcome: Number of Participants With ISTH (International Society on Thrombosis and Haemostasis) Major Bleeding
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.
Time frame: For each participant, the first occurrence of the major bleeding events according to the ISTH classification after randomization up until 2 days after permanent stop of study drug (rivaroxaban or rivaroxaban placebo).
Secondary Safety Outcome: Number of Participants With BARC (Bleeding Academic Research Consortium) Type 3b and Above Bleeding Events
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered
Time frame: For each participant, the first occurrence of the type 3b and above bleeding events according to the BARC classification after randomization up until 2 days after permanent stop of study drug (rivaroxaban or rivaroxaban placebo)
Study was conducted at 548 centers which screened participants (534 sites randomized participants) worldwide between 18 Aug 2015 (first patient's first visit) and 27 Nov 2019 (last patient's last visit).
| Milestone | Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | Rivaroxaban Placebo Bid + Aspirin 100 mg od |
|---|---|---|
| Started | 3286 | 3278 |
| Received treatment | 3256 | 3248 |
| Completed | 3275 | 3263 |
| Not completed | 11 | 15 |
| Withdrew: Lost to follow-up | 3 | 3 |
| Withdrew: Withdrawal by subject | 8 | 12 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.
| Participants | Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | Rivaroxaban Placebo Bid + Aspirin 100 mg od |
|---|---|---|
| Primary Efficacy Outcome: Number of Participants With Composite of Myocardial Infarction (MI), Ischemic Stroke, Cardiovascular Death, Acute Limb Ischemia (ALI) and Major Amputation Due to a Vascular Etiology | 508 | 584 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.
| Participants | Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | Rivaroxaban Placebo Bid + Aspirin 100 mg od |
|---|---|---|
| Primary Safety Outcome: Number of Participants With TIMI (Thrombolysis in Myocardial Infarction) Major Bleeding | 62 | 44 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.
| Participants | Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | Rivaroxaban Placebo Bid + Aspirin 100 mg od |
|---|---|---|
| Number of Participants With Composite of MI, Ischemic Stroke, Coronary Heart Disease (CHD) Death, ALI, and Major Amputation of a Vascular Etiology | 433 | 528 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.
| Participants | Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | Rivaroxaban Placebo Bid + Aspirin 100 mg od |
|---|---|---|
| Number of Participants With an Unplanned Index Limb Revascularization for Recurrent Limb Ischemia (Subsequent Index Leg Revascularization That Was Not Planned or Considered as Part of the Initial Treatment Plan at the Time of Randomization) | 584 | 655 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.
| Participants | Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | Rivaroxaban Placebo Bid + Aspirin 100 mg od |
|---|---|---|
| Number of Participants With Hospitalization for a Coronary or Peripheral Cause (Either Lower Limb) of a Thrombotic Nature | 262 | 356 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.
| Participants | Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | Rivaroxaban Placebo Bid + Aspirin 100 mg od |
|---|---|---|
| Number of Participants With Composite of MI, Ischemic Stroke, All-cause Mortality (ACM), ALI, and Major Amputation of a Vascular Etiology | 614 | 679 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.
| Participants | Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | Rivaroxaban Placebo Bid + Aspirin 100 mg od |
|---|---|---|
| Number of Participants With Composite of MI, All-cause Stroke, Cardiovascular (CV) Death, Acute Limb Ischemia (ALI), and Major Amputation of a Vascular Etiology | 514 | 588 |
| Participants | Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | Rivaroxaban Placebo Bid + Aspirin 100 mg od |
|---|---|---|
| Number of Mortality (All-cause) | 321 | 297 |
Venous thromboembolic events were reported by investigator only.
| Participants | Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | Rivaroxaban Placebo Bid + Aspirin 100 mg od |
|---|---|---|
| Number of Participants With Venous Thromboembolic (VTE) Events | 25 | 41 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.
| Participants | Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | Rivaroxaban Placebo Bid + Aspirin 100 mg od |
|---|---|---|
| Secondary Safety Outcome: Number of Participants With ISTH (International Society on Thrombosis and Haemostasis) Major Bleeding | 140 | 100 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered
| Participants | Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | Rivaroxaban Placebo Bid + Aspirin 100 mg od |
|---|---|---|
| Secondary Safety Outcome: Number of Participants With BARC (Bleeding Academic Research Consortium) Type 3b and Above Bleeding Events | 93 | 73 |
Collected over From randomization until 2 days following permanent discontinuation of the study drug. Non-serious events are listed at a 0.1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 327/3,256 (10%) | 948/3,256 (29.1%) | 725/3,256 (22.3%) |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 304/3,248 (9.4%) | 927/3,248 (28.5%) | 729/3,248 (22.4%) |
| Event | Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | Rivaroxaban Placebo Bid + Aspirin 100 mg od |
|---|---|---|
| Peripheral arterial occlusive diseaseVascular disorders | 125/3256 | 130/3248 |
| Intermittent claudicationVascular disorders | 43/3256 | 52/3248 |
| PneumoniaInfections and infestations | 40/3256 | 45/3248 |
| Peripheral ischaemiaVascular disorders | 34/3256 | 29/3248 |
| Postoperative wound infectionInfections and infestations | 27/3256 | 25/3248 |
| Peripheral artery stenosisVascular disorders | 25/3256 | 14/3248 |
| Carotid artery stenosisNervous system disorders | 22/3256 | 24/3248 |
| Coronary artery diseaseCardiac disorders | 15/3256 | 21/3248 |
| Atrial fibrillationCardiac disorders | 19/3256 | 20/3248 |
| GangreneInfections and infestations | 16/3256 | 20/3248 |
| Event | Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | Rivaroxaban Placebo Bid + Aspirin 100 mg od |
|---|---|---|
| Pain in extremityMusculoskeletal and connective tissue disorders | 47/3256 | 52/3248 |
| HypertensionVascular disorders | 49/3256 | 50/3248 |
| Atrial fibrillationCardiac disorders | 31/3256 | 48/3248 |
| Intermittent claudicationVascular disorders | 39/3256 | 43/3248 |
| Peripheral arterial occlusive diseaseVascular disorders | 34/3256 | 31/3248 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 18/3256 | 32/3248 |
| NasopharyngitisInfections and infestations | 21/3256 | 30/3248 |
| Back painMusculoskeletal and connective tissue disorders | 23/3256 | 30/3248 |
| AnaemiaBlood and lymphatic system disorders | 29/3256 | 23/3248 |
| DizzinessNervous system disorders | 23/3256 | 26/3248 |
| Age, Continuous(Years) | Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | Rivaroxaban Placebo Bid + Aspirin 100 mg od | Total |
|---|---|---|---|
| Median | 67.0 (49 to 93) | 67.0 (50 to 95) | 67 (49 to 95) |
| Sex: Female, Male(Participants) | Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | Rivaroxaban Placebo Bid + Aspirin 100 mg od | Total |
|---|---|---|---|
| Female | 847 | 857 | 1704 |
| Male | 2439 | 2421 | 4860 |
| Race (NIH/OMB)(Participants) | Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | Rivaroxaban Placebo Bid + Aspirin 100 mg od | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 4 | 5 |
| Asian | 484 | 482 | 966 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 84 | 71 | 155 |
| White | 2647 | 2656 | 5303 |
| More than one race | 1 | 2 | 3 |
| Unknown or Not Reported | 69 | 62 | 131 |
Showing the first 100 of 533 sites across 34 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2015 to primary completion in Nov 2019, 51 months.
Results were first posted in Dec 2020, 1 year after primary completion.
Of 26 phase 3 interventional studies under Peripheral Arterial Disease, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 58. This study's 51 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rivaroxaban